NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts(1) (a non-GAAP financial measure) guidance.
“Royalty Pharma had an outstanding year in 2021, building off the strong momentum we achieved in 2020,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We delivered impressive growth and we announced $3.0 billion in transactions, which further diversify our portfolio and enhance our long-term outlook. Royalty Pharma is uniquely positioned as the trusted partner of choice in delivering creative solutions to fund the acceleration in life sciences innovation, and we are tracking well ahead of our capital deployment targets. These strong fundamental tailwinds underpin our confidence in delivering attractive, compounding growth in the years ahead.”
Fourth quarter and full year 2021 GAAP financial results reflect expansion of development-stage portfolio
Fourth quarter and full year 2021 non-GAAP financial results show strong double-digit growth
Multiple positive clinical and regulatory updates in the fourth quarter
Expanded portfolio with innovative, long duration therapies across diverse therapeutic areas
Financial guidance for full year 2022 (excludes contributions from new transactions)
Financial Summary | Three months ended December 31 | Twelve months ended December 31 | ||||||||||
(unaudited) | ||||||||||||
($ and shares in millions) | 2021 | 2020 | Change | 2021 | 2020 | Change | ||||||
Net cash provided by operating activities (GAAP) | 490 | 566 | (13 | )% | 2,018 | 2,035 | (1 | )% | ||||
Net cash used in investing activities (GAAP) | (552 | ) | (832 | ) | (34 | )% | (1,870 | ) | (2,759 | ) | (32 | )% |
Net cash (used in)/provided by financing activities (GAAP) | (198 | ) | (277 | ) | (29 | )% | 385 | 1,487 | (74 | )% | ||
Total income and other revenues (GAAP) | 576 | 572 | 1 | % | 2,289 | 2,122 | 8 | % | ||||
Adjusted Cash Receipts (1) (non-GAAP) | 543 | 484 | 12 | % | 2,129 | 1,800 | 18 | % | ||||
Adjusted Cash Flow (2) (non-GAAP) | 488 | 423 | 15 | % | 1,767 | 1,483 | 19 | % | ||||
Fully diluted Class A shares outstanding | 607 | 607 | 0 | % | 607 | 607 | 0 | % |
Fourth Quarter 2021 Financial Results
Three months ended December 31 | ||||||||
(unaudited) | ||||||||
($ in millions) | 2021 | 2020 | Change | |||||
Net cash provided by operating activities (GAAP) | 490 | 566 | (13 | )% | ||||
Royalty Receipts: | Marketer: | Therapeutic Area: | ||||||
Cystic fibrosis franchise | Vertex | Rare disease | 196 | 159 | 24 | % | ||
Tysabri | Biogen | Neurology | 94 | 93 | 2 | % | ||
Imbruvica | AbbVie, J&J | Cancer | 89 | 85 | 4 | % | ||
Promacta | Novartis | Hematology | 49 | 42 | 18 | % | ||
Xtandi | Pfizer, Astellas | Cancer | 41 | 39 | 5 | % | ||
Januvia, Janumet, Other DPP-IVs | Merck & Co., others | Diabetes | 38 | 40 | (4 | )% | ||
Nurtec ODT/Biohaven payment* | Biohaven, Pfizer | Neurology | 19 | 3 | nm | |||
Tremfya | Johnson & Johnson | Immunology | 19 | — | n/a | |||
Cabometyx/Cometriq | Exelixis, Ipsen, Takeda | Cancer | 12 | — | n/a | |||
Prevymis | Merck & Co. | Infectious disease | 10 | 8 | 23 | % | ||
Farxiga/Onglyza | AstraZeneca | Diabetes | 9 | 8 | 11 | % | ||
Evrysdi | Roche | Rare disease | 6 | 0 | nm | |||
Trodelvy | Gilead | Cancer | 5 | 2 | 140 | % | ||
Crysvita | Ultragenyx, Kyowa Kirin | Rare disease | 5 | 3 | 35 | % | ||
Erleada | Johnson & Johnson | Cancer | 4 | 3 | 67 | % | ||
Emgality | Lilly | Neurology | 4 | 3 | 52 | % | ||
IDHIFA | Bristol Myers Squibb | Cancer | 4 | 3 | 36 | % | ||
Orladeyo | BioCryst | Rare disease | 3 | — | n/a | |||
HIV franchise | Gilead, others | Infectious disease | 1 | 78 | (99 | )% | ||
Tazverik | Epizyme | Cancer | 1 | 0 | 142 | % | ||
Oxlumo | Alnylam | Rare disease | 1 | — | n/a | |||
Other products(3) | 49 | 57 | (14 | )% | ||||
Total royalty receipts | 659 | 627 | 5 | % | ||||
Distributions to non-controlling interest | (116 | ) | (143 | ) | (19 | )% | ||
Adjusted Cash Receipts(1) (non-GAAP) | 543 | 484 | 12 | % |
Amounts shown in the table may not add due to rounding.
*Includes royalty receipts for Nurtec ODT of $3.4 million and the redemption of the Series A Biohaven Preferred Shares of $16 million (presented as proceeds from available for sale debt securities on the Statement of Cash Flows) in the fourth quarter of 2021 and $0.4 million of royalty receipts for Nurtec ODT and a $3 million payment related to an expired option to exercise additional funding on the Biohaven Series A Preferred Shares in the fourth quarter of 2020.
Net cash provided by operating activities (GAAP) was $490 million in the fourth quarter of 2021, a decrease of 13%, and $2,018 million for full year 2021, a decrease of 1%, compared to the same periods in 2020. The decreases in the fourth quarter of 2021 and full year 2021 resulted primarily from upfront payments of $103 million to acquire additional royalties on BCX9930, a development-stage product, from BioCryst in the fourth quarter of 2021 and $90 million to acquire royalties on pelabresib and CPI-0209, both development-stage products, from MorphoSys in the third quarter of 2021. These decreases were partially offset by higher cash collections from financial royalty assets.
Total royalty receipts were $659 million in the fourth quarter of 2021, an increase of 5%, and $2,609 million for full year 2021, an increase of 11%, compared to the same periods in 2020. The increase in the fourth quarter of 2021 was largely attributable to the performance of the cystic fibrosis franchise, Biohaven payments, Promacta and the addition of new royalties. This increase was partially offset by a decline in royalties from the HIV franchise which reached the end of its royalty term in 2021. Growth for full year 2021 was also positively impacted by the performance of the cystic fibrosis franchise, new royalty acquisitions, Biohaven payments, Imbruvica and Tysabri, and partially offset by the end of the HIV franchise royalty term compared to the prior year.
Drivers of royalty receipts in the fourth quarter of 2021 and full year 2021 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
Distributions to non-controlling interest, which reduce royalty receipts to arrive at Adjusted Cash Receipts(1), were $116 million in the fourth quarter of 2021, a decrease of 19%, compared to the same period of 2020, primarily due to the end of the royalty term for the HIV franchise. Distributions to non-controlling interest were $480 million in full year 2021, a decrease of 12%, compared to the prior year period. This decrease is primarily due to a non-recurring distribution to the Legacy Investors Partnerships in connection with the Exchange Offer Transactions(9) that occurred in the first quarter of 2020. Partially offsetting the decrease was a one-time of $8 million distribution to non-controlling interest in full year 2021 related to the $45 million milestone payment received on Soliqua.
As a percent of total royalty receipts, distributions to non-controlling interest decreased to 18% in both the fourth quarter of 2021 and full year 2021, compared to 23% in the same periods of 2020. This was driven primarily by the addition of new royalties with no non-controlling interest contribution and reduced royalties from products with a higher percentage contribution to non-controlling interest, such as the HIV franchise.
Adjusted Cash Receipts(1) (non-GAAP) were $543 million in the fourth quarter of 2021, an increase of 12%, and $2,129 million in 2021, an increase of 18%, compared to the same periods of 2020. These increases were driven by royalty receipts from the cystic fibrosis franchise, Imbruvica, Biohaven payments and the addition of new royalties, partially offset by a decline in HIV franchise and legacy “Other products,” such as Lyrica and Letairis.
Adjusted EBITDA(4) (non-GAAP) is comprised of Adjusted Cash Receipts less payments for operating and professional costs. Adjusted EBITDA was $494 million in the fourth quarter of 2021, a 14% increase, compared to $434 million in the fourth quarter of 2020. Adjusted EBITDA was $1,944 million in full year 2021, an increase of 20%, compared to full year 2020. Growth in Adjusted EBITDA was largely attributable to the following items:
Adjusted Cash Flow(2) (non-GAAP) is comprised of Adjusted EBITDA(4) less ongoing development-stage funding payments, net interest paid and miscellaneous other items. Adjusted Cash Flow was $488 million in the fourth quarter of 2021, a 15% increase, compared to Adjusted Cash Flow of $423 million for the same period of 2020. The increase primarily resulted from the growth in Adjusted Cash Receipts(1).
Adjusted Cash Flow was $1,767 million in full year 2021, an increase of 19%, compared to the prior year period, which primarily resulted from the growth in Adjusted Cash Receipts(1). This growth was partially offset by an increase in interest paid due to the shift to semi-annual interest payments with the issuance of $6 billion of senior unsecured notes completed in September 2020, for which interest payments began in 2021.
A more comprehensive discussion of the non-GAAP measures utilized by Royalty Pharma to manage its business can be found in the section of this press release entitled ‘Use of Non-GAAP Measures.’
Key Developments Relating to the Portfolio
The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.
In December 2021, Cytokinetics announced the U.S. FDA granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic oHCM based on results from the Phase 2 REDWOOD-HCM trial.
In November 2021, Gilead announced that the European Commission (EC) granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC’s decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician’s choice of chemotherapy.
In November 2021, Biohaven announced a strategic collaboration with Pfizer for the commercialization of rimegepant and zavegepant outside of the United States. Royalty Pharma is entitled to royalties on annual worldwide net sales of rimegepant (commercialized as Nurtec ODT in the U.S.) and zavegepant.
Summary of Recent Royalty Acquisition Activity
Liquidity and Capital Resources
Full Year 2022 Financial Guidance
Royalty Pharma has provided guidance for full year 2022 as follows:
Provided February 15, 2022 | |
Adjusted Cash Receipts(1) (non-GAAP) excluding new transactions announced after the date of this release | $2,225 million to $2,300 million |
Royalty Pharma expects payments for operating and professional costs to be approximately 9% of Adjusted Cash Receipts in 2022.
Royalty Pharma expects to make its first semi-annual interest payment on the 2021 Notes in March 2022, resulting in total expected interest paid to be approximately $170 million in 2022. Based on the semi-annual interest payment schedule of Royalty Pharma’s existing bonds, interest paid is anticipated to be $86 million in the first quarter of 2022, $83 million in the third quarter of 2022 and a de minimis amount paid in the second and fourth quarters of 2022. The projection assumes no additional debt financing in 2022.
Royalty Pharma today provides this guidance based on its most up-to-date view on its prospects. This guidance assumes no major unforeseen adverse events and excludes the contributions from transactions announced subsequent to the date of this press release. Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the company.
Royalty Pharma has not reconciled its non-GAAP 2022 guidance to the most directly comparable GAAP measure, net cash provided by operating activities, at this time due to the inherent difficulty in accurately forecasting and quantifying certain amounts that are necessary for such reconciliation, including, primarily, payments for operating and professional costs, distributions from non-consolidated affiliates and interest received. Royalty Pharma is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to project net cash provided by operating activities at this time.
Financial Results Call
Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2021 results today at 8:00 a.m., Eastern Time. A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. Please allow at least five minutes to register and access the presentation. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. To ask a question during the live broadcast or listen without internet access, please dial in at least 15 minutes in advance to ensure a timely connection to the call. The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253, or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 6819125.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnsons’ Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.
For further information, please reference Royalty Pharma's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.
Use of Non-GAAP Measures
Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to Royalty Pharma's GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because operating performance is a function of liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures Royalty Pharma uses in the same manner. Royalty Pharma compensates for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being net cash provided by operating activities.
Royalty Pharma believes that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about its operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising its operating results. Management strongly believes that Royalty Pharma's significant operating cash flow is one of the attributes that attracts potential investors to its business.
In addition, Royalty Pharma believes that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Both measures are an indication of the strength of the company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.
Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing liquidity and is a key component of certain material covenants contained within the company’s credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of Royalty Pharma's liquidity.
Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the company’s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. Royalty Pharma believes that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in Royalty Pharma's industry.
The non-GAAP financial measures used in this press release have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma's results as reported under GAAP. The company has provided a reconciliation of each non-GAAP financial measure, except for its non-GAAP outlook to the most directly comparable GAAP financial measure, in each case being net cash provided by operating activities at Table 5.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
[email protected]
Royalty Pharma plc
Condensed Consolidated Statements of Operations (unaudited)
Table 1
Three months ended December 31 | Twelve months ended December 31 | |||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | ||
Income and other revenues: | ||||||
Income from financial royalty assets | 526 | 524 | 2,065 | 1,960 | ||
Revenue from intangible royalty assets | 32 | 40 | 171 | 143 | ||
Other royalty income | 18 | 7 | 53 | 19 | ||
Total income and other revenues | 576 | 572 | 2,289 | 2,122 | ||
Operating expenses: | ||||||
Provision for changes in expected cash flows from financial royalty assets | 267 | 129 | 453 | 231 | ||
Research and development funding expense | 104 | 8 | 200 | 26 | ||
Amortization of intangible assets | 6 | 6 | 23 | 23 | ||
General and administrative expenses | 46 | 50 | 183 | 182 | ||
Other operating expenses | — | 65 | — | 65 | ||
Total operating expenses, net | 422 | 258 | 859 | 527 | ||
Operating income | 153 | 314 | 1,431 | 1,595 | ||
Other expense/(income): | ||||||
Equity in losses/(earnings) of non-consolidated affiliates | 38 | (10) | 19 | (44) | ||
Interest expense | 47 | 38 | 166 | 157 | ||
Other expense/(income), net | 15 | (80) | 4 | (219) | ||
Total other expense/(income), net | 100 | (53) | 190 | (107) | ||
Consolidated net income before tax | 54 | 367 | 1,241 | 1,702 | ||
Income tax expense | — | — | — | — | ||
Consolidated net income | 54 | 367 | 1,241 | 1,702 | ||
Net income attributable to non-controlling interest | 46 | 196 | 621 | 727 | ||
Net income attributable to controlling interest | 8 | 171 | 620 | 975 |
Amounts may not add due to rounding.
Royalty Pharma plc
Selected Balance Sheet Data (unaudited)
Table 2
($ in millions) | As of December 31, 2021 | As of December 31, 2020 |
Cash and cash equivalents | 1,541 | 1,009 |
Marketable securities | 582 | 983 |
Total financial royalty assets, net | 14,333 | 12,955 |
Total assets | 17,516 | 16,020 |
Long-term debt | 7,096 | 5,817 |
Total liabilities | 7,267 | 6,124 |
Total shareholders’ equity | 10,249 | 9,896 |
Royalty Pharma plc
Condensed Consolidated Statements of Cash Flows (unaudited)
Table 3
Three months ended December 31 | Twelve months ended December 31 | |||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | ||||
Cash flows from operating activities: | ||||||||
Cash collections from financial royalty assets | 583 | 573 | 2,316 | 2,122 | ||||
Cash collections from intangible royalty assets | 38 | 40 | 151 | 144 | ||||
Other royalty cash collections | 17 | 6 | 44 | 18 | ||||
Distributions from non-consolidated affiliates | 6 | 6 | 34 | 42 | ||||
Interest received | 0 | 0 | 3 | 8 | ||||
Derivative collateral received | — | — | 35 | 45 | ||||
Derivative collateral posted | — | — | (35 | ) | — | |||
Termination payments on derivative instruments | — | — | (16 | ) | (35 | ) | ||
Ongoing development-stage funding payments | (1 | ) | (2 | ) | (7 | ) | (20 | ) |
Upfront development-stage funding payments | (103 | ) | (6 | ) | (193 | ) | (6 | ) |
Payments for operating and professional costs | (49 | ) | (50 | ) | (185 | ) | (180 | ) |
Interest paid | (1 | ) | (1 | ) | (130 | ) | (103 | ) |
Net cash provided by operating activities | 490 | 566 | 2,018 | 2,035 | ||||
Cash flows from investing activities: | ||||||||
Distributions from non-consolidated affiliates | — | — | 1 | 15 | ||||
Investments in non-consolidated affiliates | (7 | ) | (11 | ) | (35 | ) | (40 | ) |
Purchases of equity securities | (35 | ) | — | (135 | ) | (50 | ) | |
Proceeds from equity securities | — | 385 | 116 | 385 | ||||
Purchases of available for sale debt securities | (18 | ) | — | (70 | ) | — | ||
Proceeds from available for sale debt securities | 16 | 3 | 63 | 3 | ||||
Purchases of marketable securities | (441 | ) | (610 | ) | (1,197 | ) | (1,705 | ) |
Proceeds from sales and maturities of marketable securities | 105 | 206 | 1,598 | 815 | ||||
Acquisitions of financial royalty assets | (172 | ) | (805 | ) | (2,192 | ) | (2,182 | ) |
Milestone payments | — | — | (19 | ) | — | |||
Net cash used in investing activities | (552 | ) | (832 | ) | (1,870 | ) | (2,759 | ) |
Cash flows from financing activities: | ||||||||
Distributions to shareholders/unitholders | — | — | — | (285 | ) | |||
Distributions to non-controlling interest | (116 | ) | (143 | ) | (480 | ) | (544 | ) |
Distributions to non-controlling interest- other | (34 | ) | (107 | ) | (154 | ) | (181 | ) |
Dividends to shareholders | (74 | ) | (58 | ) | (285 | ) | (112 | ) |
Contributions from non-controlling interest- R&D | 1 | 2 | 7 | 8 | ||||
Contributions from non-controlling interest- other | 25 | 29 | 37 | 59 | ||||
Scheduled repayments of long-term debt | — | — | — | (94 | ) | |||
Repayments of long-term debt | — | — | — | (11,116 | ) | |||
Proceeds from issuance of long-term debt, net of discount | — | — | 1,273 | 11,891 | ||||
Debt issuance costs and other | (1 | ) | (0 | ) | (13 | ) | (47 | ) |
Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs | — | (1 | ) | — | 1,909 | |||
Net cash (used in)/provided by financing activities | (198 | ) | (277 | ) | 385 | 1,487 | ||
Net change in cash and cash equivalents | (260 | ) | (544 | ) | 532 | 762 | ||
Cash and cash equivalents, beginning of year | 1,801 | 1,553 | 1,009 | 246 | ||||
Cash and cash equivalents, end of year | 1,541 | 1,009 | 1,541 | 1,009 |
Amounts may not add due to rounding.
Royalty Pharma plc
Non-GAAP Financial Measures (unaudited)
Table 4
Three months ended December 31, | Twelve months ended December 31, | |||||||||||
($ in millions) | 2021 | 2020 | Change | 2021 | 2020 | Change | ||||||
Net cash provided by operating activities (GAAP) | 490 | 566 | (13 | )% | 2,018 | 2,035 | (1 | )% | ||||
Products: | ||||||||||||
Cystic fibrosis franchise | 196 | 159 | 24 | % | 702 | 551 | 27 | % | ||||
Tysabri | 94 | 93 | 2 | % | 369 | 346 | 7 | % | ||||
Imbruvica | 89 | 85 | 4 | % | 353 | 322 | 10 | % | ||||
Promacta | 49 | 42 | 18 | % | 174 | 144 | 21 | % | ||||
Xtandi | 41 | 39 | 5 | % | 158 | 146 | 8 | % | ||||
Januvia, Janumet, Other DPP-IVs | 38 | 40 | (4 | )% | 151 | 144 | 5 | % | ||||
Nurtec ODT/Biohaven payment* | 19 | 3 | nm | 70 | 4 | nm | ||||||
Tremfya | 19 | — | n/a | 36 | — | n/a | ||||||
Cabomeytx/Cometriq | 12 | — | n/a | 34 | — | n/a | ||||||
Prevymis | 10 | 8 | 23 | % | 38 | 21 | 75 | % | ||||
Farxiga/Onglyza | 9 | 8 | 11 | % | 36 | 25 | 45 | % | ||||
Evrysdi | 6 | 0 | nm | 16 | 0 | nm | ||||||
Trodelvy | 5 | 2 | 140 | % | 13 | 3 | nm | |||||
Crysvita | 5 | 3 | 35 | % | 17 | 9 | 77 | % | ||||
Erleada | 4 | 3 | 67 | % | 14 | 8 | 81 | % | ||||
Emgality | 4 | 3 | 52 | % | 15 | 10 | 62 | % | ||||
IDHIFA | 4 | 3 | 36 | % | 12 | 6 | 103 | % | ||||
Orladeyo | 3 | — | n/a | 7 | — | n/a | ||||||
HIV franchise | 1 | 78 | (99 | )% | 78 | 294 | (73 | )% | ||||
Tazverik | 1 | 0 | 142 | % | 3 | 1 | nm | |||||
Oxlumo | 1 | — | n/a | 1 | — | n/a | ||||||
Other products (3) | 49 | 57 | (14 | )% | 311 | 311 | 0 | % | ||||
Total royalty receipts | 659 | 627 | 5 | % | 2,609 | 2,344 | 11 | % | ||||
Distributions to non-controlling interest | (116 | ) | (143 | ) | (19 | )% | (480 | ) | (544 | ) | (12 | )% |
Adjusted Cash Receipts(1) (non-GAAP) | 543 | 484 | 12 | % | 2,129 | 1,800 | 18 | % | ||||
Payments for operating and professional costs | (49 | ) | (50 | ) | (2 | )% | (185 | ) | (180 | ) | 3 | % |
Adjusted EBITDA(4) (non-GAAP) | 494 | 434 | 14 | % | 1,944 | 1,621 | 20 | % | ||||
Interest paid, net | (1 | ) | (1 | ) | 0 | % | (127 | ) | (95 | ) | 33 | % |
Investments in non-consolidated affiliates | (7 | ) | (11 | ) | (40 | )% | (35 | ) | (40 | ) | (13 | )% |
Ongoing development-stage funding payments | (1 | ) | (2 | ) | (69 | )% | (7 | ) | (20 | ) | (66 | )% |
Other | — | — | n/a | (16 | ) | 10 | (264 | )% | ||||
Contributions from non-controlling interest- R&D | 1 | 2 | (44 | )% | 7 | 8 | (13 | )% | ||||
Adjusted Cash Flow(2) (non-GAAP) | 488 | 423 | 15 | % | 1,767 | 1,483 | 19 | % |
Amounts may not add due to rounding.
*Includes royalty receipts for Nurtec ODT of $0.4 million and a $3 million payment related to an expired option to exercise additional funding on the Biohaven Series A Preferred Shares in the fourth quarter of 2020. Includes royalty receipts for Nurtec ODT of $3 million and $8 million for the fourth quarter of 2021 and full year 2021, respectively. In 2021, we also received quarterly redemptions of $16 million of the Series A Biohaven Preferred Shares (presented as proceeds from available for sale debt securities on the Statement of Cash Flows).
Royalty Pharma plc
GAAP to Non-GAAP Reconciliation (unaudited)
Table 5
Three months ended December 31 | Twelve months ended December 31 | |||||||
($ in millions) | 2021 | 2020 | 2021 | 2020 | ||||
Net cash provided by operating activities (GAAP) | 490 | 566 | 2,018 | 2,035 | ||||
Adjustments: | ||||||||
Proceeds from available for sale debt securities(5)(6) | 16 | 3 | 63 | 3 | ||||
Distributions from non-consolidated affiliates - investing(6) | — | — | 1 | 15 | ||||
Interest paid, net(6) | 1 | 1 | 127 | 95 | ||||
Ongoing development-stage funding payments(7) | 1 | 2 | 7 | 20 | ||||
Upfront development-stage funding payments(7) | 103 | 6 | 193 | 6 | ||||
Payments for operating and professional costs | 49 | 50 | 185 | 180 | ||||
Termination payments on derivative instruments | — | — | 16 | 35 | ||||
Distributions to non-controlling interest(6) | (116 | ) | (143 | ) | (480 | ) | (544 | ) |
Derivative collateral received, net(6) | — | — | — | (45 | ) | |||
Adjusted Cash Receipts(1) (non-GAAP) | 543 | 484 | 2,129 | 1,800 | ||||
Net cash provided by operating activities (GAAP) | 490 | 566 | 2,018 | 2,035 | ||||
Adjustments: | ||||||||
Proceeds from available for sale debt securities(5)(6) | 16 | 3 | 63 | 3 | ||||
Distributions from non-consolidated affiliates - investing(6) | — | — | 1 | 15 | ||||
Interest paid, net(6) | 1 | 1 | 127 | 95 | ||||
Ongoing development-stage funding payments(7) | 1 | 2 | 7 | 20 | ||||
Upfront development-stage funding payments(7) | 103 | 6 | 193 | 6 | ||||
Termination payments on derivative instruments | — | — | 16 | 35 | ||||
Distributions to non-controlling interests(6) | (116 | ) | (143 | ) | (480 | ) | (544 | ) |
Derivative collateral received, net(6) | — | — | — | (45 | ) | |||
Adjusted EBITDA(4) (non-GAAP) | 494 | 434 | 1,944 | 1,621 | ||||
Net cash provided by operating activities (GAAP) | 490 | 566 | 2,018 | 2,035 | ||||
Adjustments: | ||||||||
Proceeds from available for sale debt securities(5)(6) | 16 | 3 | 63 | 3 | ||||
Distributions from non-consolidated affiliates - investing(6) | — | — | 1 | 15 | ||||
Upfront development-stage funding payments(7) | 103 | 6 | 193 | 6 | ||||
Distributions to non-controlling interests(6) | (116 | ) | (143 | ) | (480 | ) | (544 | ) |
Investment in non-consolidated affiliates(6)(8) | (7 | ) | (11 | ) | (35 | ) | (40 | ) |
Contribution from non-controlling interest- R&D(6) | 1 | 2 | 7 | 8 | ||||
Adjusted Cash Flow(2) (non-GAAP) | 488 | 423 | 1,767 | 1,483 |
Amounts may not add due to rounding.
Notes
(1) | Adjusted Cash Receipts is a measure calculated with inputs directly from the Statement of Cash Flows and includes (1) royalty receipts: (i) cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from non-consolidated affiliates, plus (2) Proceeds from available for sale debt securities, and less (3) Distributions to non-controlling interest, which represents contractual distributions to historical non-controlling interest attributable to a de minimis interest in Royalty Pharma Collection Trust held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships’ ownership of approximately 18% in Royalty Pharma Investments. See Royalty Pharma’s Annual Report on Form 10-K filed with the SEC on February 15, 2022 for additional discussion. See GAAP to Non-GAAP reconciliation at Table 5. | |
(2) | Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Ongoing development-stage funding payments, (2) interest paid, net of interest received, (3) other (including Derivative collateral posted, net of Derivative collateral received and Termination payments on derivative instruments) and (4) Investments in non-consolidated affiliates, and plus (1) Contributions from non-controlling interest- R&D, all directly reconcilable to the Statement of Cash Flows. See GAAP to Non-GAAP reconciliation at Table 5. | |
(3) | Other products primarily include royalties on the following products: Cimzia, Entyvio, Letairis, Lexiscan, Lyrica, Myozyme, Mircera, Nesina, Soliqua and contributions from the Legacy SLP Interest. | |
(4) | Adjusted EBITDA is important to lenders and is defined under the credit agreement as Adjusted Cash Receipts less payments for operating and professional costs. Operating and professional costs are comprised of Payments for operating and professional costs from the Statement of Cash Flows. See GAAP to Non-GAAP reconciliation at Table 5. | |
(5) | Receipts from the redemption of Royalty Pharma’s Series A Biohaven Preferred Shares are presented as Proceeds from available for sale debt securities on the Statement of Cash Flows. | |
(6) | The table below shows the line item for each adjustment and the direct location for such line item on the Statement of Cash Flows. |
Reconciling adjustment | Statement of Cash Flows classification |
Proceeds from available for sale debt securities | Investing activities |
Investments in non-consolidated affiliates | Investing activities |
Distributions to non-controlling interest | Financing activities |
Interest paid, net | Operating activities (Interest paid less Interest received) |
Derivative collateral received, net | Operating activities (Derivative collateral received less Derivative collateral posted) |
Contributions from non-controlling interest- R&D | Financing activities |
Distributions from non-consolidated affiliates - investing | Investing activities |
(7) | Royalty Pharma’s lenders consider all payments made to support R&D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing and upfront development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for R&D funding payments while Adjusted Cash Flow only reflects the add-back for the upfront portion of development-stage funding payments due to the fact that ongoing development-stage funding payments are considered an ongoing business expense. | |
(8) | Royalty Pharma considers all payments to fund its operating joint ventures that are performing R&D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by Royalty Pharma’s equity method investees, the Avillion entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA. | |
(9) | In connection with its IPO, Royalty Pharma consummated an exchange offer on February 11, 2020. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under Royalty Pharma’s new credit facility and (ii) the issuance of additional interests in RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.” |
Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:
We refer to these transactions collectively as the “Reorganization Transactions.” See Royalty Pharma’s Annual Report on Form 10-K filed with the SEC on February 15, 2022 for additional discussion.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member